I gave a hold rating to Diageo PLC ( DGEAF ) in June, as I wanted to see more signs of recovery, especially in the core spirits segment, and hence, I believed one should just wait andI'm a passionate investor with a strong foundation in fundamental analysis and a keen eye for identifying undervalued companies with long-term growth potential. My investment approach is a blend of value investing principles and a focus on long-term growth. I believe in buying quality companies at a discount to their intrinsic ...

I am focused on growth and dividend income. My personal strategy revolves around setting myself up for an easy retirement by creating a portfolio which focuses on compounding dividend income and growth. Dividends are an intricate part of my strategy as I have structured my portfolio to have monthly dividend income which grows through dividend reinvestment and yearly increases. Feel free to reach out to me on Seeking AlphaAnalyst’s Disclosure:I/we have a beneficial long position in the shares of STWD either ...

Micron Technology, Inc. (NASDAQ:MU) will release earnings results for its first quarter after the closing bell on Wednesday, Dec. 17.Analysts expect the company to report quarterly earnings at $3.93 per share, up from $1.79 per share in the year-ago period. The consensus estimate for Micron’s quarterly revenue is $12.81 billion, compared to $8.71 billion a year earlier, according to data from Benzinga Pro.The estimated revenue would mark a new record for the company, surpassing the $11.31 billion reported i ...

Core Insights - Recent secondary offerings from biotech companies Immunovant Inc. and Kymera Therapeutics Inc. have been observed, indicating a trend in the sector [1] Company Summaries - Immunovant Inc. has engaged in a secondary offering, which may impact its capital structure and investor sentiment [1] - Kymera Therapeutics Inc. has also participated in a secondary offering, reflecting its strategic financial decisions within the current market environment [1]

Core Insights - VolitionRx Limited has made significant progress in 2025, focusing on the commercialization of its Nu.Q® platform for human diagnostics, with key milestones achieved in cancer and sepsis detection [2][3][4] Group 1: Business Developments - The company received its first order for Nu.Q® Cancer assays for clinical certification in lung cancer and included the Nu.Q® NETs assay in a government-backed program in France for early sepsis detection, valued at approximately $7.3 million [3][4] - Volition signed two licensing agreements with major companies, Werfen and Hologic, marking a strategic move into the human diagnostics market [5] - The company is in discussions with around 10 leading diagnostic and liquid biopsy companies to secure additional licensing agreements, anticipating announcements throughout 2026 [6][7] Group 2: Financial Opportunities - The Total Addressable Markets (TAMs) for Volition's technologies are substantial, including $2.3 billion for lung cancer screening, $23 billion for multi-cancer early detection, and $2.8 billion for sepsis early detection [11] - The company aims to replicate its successful licensing strategy in the veterinary market within the human diagnostics space, with potential for diverse deal structures and recurring revenue [7][10] Group 3: Scientific and Clinical Progress - Volition's Nu.Q® NETs assay is being evaluated in over 20 hospitals across 10 countries for various clinical use cases, indicating its potential to become a routine blood test [8] - The company has achieved significant scientific advancements, including the development of a lateral flow test for quantifying nucleosomes, which aids in clinical decision-making [10] - A large-scale study demonstrated that the Nu.Q® NETs H3.1 biomarker is an independent predictor of mortality in sepsis patients, showcasing the assay's clinical relevance [10]

Micron Technology, Inc. (NASDAQ:MU) will release earnings results for its first quarter after the closing bell on Wednesday, Dec. 17.Analysts expect the company to report quarterly earnings at $3.93 per share, up from $1.79 per share in the year-ago period. The consensus estimate for Micron’s quarterly revenue is $12.81 billion, compared to $8.71 billion a year earlier, according to data from Benzinga Pro.The estimated revenue would mark a new record for the company, surpassing the $11.31 billion reported i ...

Core Viewpoint - Tiziana Life Sciences has initiated a Phase 2 clinical trial for intranasal foralumab, targeting early Alzheimer's disease, marking a significant step in exploring immunomodulatory therapies for neuroinflammation [1][3][7]. Group 1: Clinical Trial Details - The Phase 2 trial is randomized and placebo-controlled, assessing the safety, tolerability, and potential efficacy of intranasal foralumab as both a monotherapy and in combination with FDA-approved anti-amyloid therapies, lecanemab or donanemab [4]. - Primary endpoints of the trial include neuroinflammation measured by TSPO-PET imaging, cognitive function, and changes in amyloid and tau biomarkers, with interim data expected in 2026 [4]. Group 2: Scientific Rationale - TSPO-PET imaging data indicates persistent microglial activation in Alzheimer's patients, even after treatment with anti-amyloid therapies, highlighting the need for therapies that address residual neuroinflammation [2]. - Intranasal foralumab is designed to modulate immune responses and reduce activated microglia, potentially slowing disease progression in early Alzheimer's disease [2][3]. Group 3: Company Insights - Gabriele Cerrone, Chairman & Founder, emphasized the importance of this trial in exploring a novel approach to Alzheimer's treatment, building on previous data showing foralumab's ability to reduce microglial activation in multiple sclerosis patients [3]. - Ivor Elrifi, CEO, expressed enthusiasm for the rapid progress from enrollment to first patient dosing, reflecting the urgent need for new treatment strategies beyond amyloid clearance [3]. Group 4: About Foralumab - Foralumab is a fully human anti-CD3 monoclonal antibody that stimulates T regulatory cells when administered intranasally, with previous studies showing positive outcomes in patients with non-active secondary progressive multiple sclerosis [5][6]. - It is the only fully human anti-CD3 monoclonal antibody currently in clinical development, representing a novel treatment avenue for neuroinflammatory and neurodegenerative diseases [6]. Group 5: Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies using alternative drug delivery technologies, aiming to improve efficacy, safety, and tolerability compared to traditional intravenous delivery methods [6][8].

FRESNO, Calif.--(BUSINESS WIRE)--Community West Bancshares (NASDAQ: CWBC), Fresno, California, parent company of Community West Bank and United Security Bancshares (NASDAQ: UBFO), parent company of United Security Bank, Fresno, California, announced today that they had signed a definitive merger agreement pursuant to which the companies will combine in an all-stock merger transaction. Following the merger of United Security Bancshares with and into Community West Bancshares, United Security Ban. ...

Uniform Labs, a blockchain infrastructure company founded by former Standard Chartered, UniCredit and other digital banking executives, has put its institutional liquidity protocol Multiliquid into production following build, audit and testing phases, the company said in a press release Wednesday. Multiliquid is designed to allow institutions to swap instantly, around the clock, between blue-chip tokenized money market funds and stablecoins, aiming to remove the days-long redemption lags and liquidity con ...

Core Viewpoint - The analyst has assigned a hold rating to Diageo PLC (DGEAF) in June, indicating a desire for more signs of recovery in the core spirits segment before making further investment decisions [1]. Company Analysis - The investment approach focuses on identifying undervalued companies with long-term growth potential, emphasizing a blend of value investing principles and long-term growth [1]. - The strategy involves purchasing quality companies at a discount to their intrinsic value and holding them to allow for compounding of earnings and shareholder returns [1].